Background The association between computed tomography (CT) imaging characteristics and clinical growth rate of multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) have not been reported. Our study focused on the correlation of CT imaging and growth rate to investigate the distinguished characteristics in MCRNLMP versus renal cysts, and explore the optimized management.Methods Data regarding 1520 patients including 1,444 patients with renal cysts and 76 patients with MCRNLMP who underwent renal cyst decompression, radical nephrectomy, or nephron sparing surgery due to renal cystic disease between Jan 2013 and Dec 2021 in our institution were retrospectively collected and analyzed. Bosniak classification for imaging modality and the 2016 WHO criteria for clinic pathology were used for detection of MCRNLMP.Results In our study, MCRNLMP accounted for 1.48% of patients with “simple renal cysts”, 5.26% of the patients with “complex renal cysts”, and 12.11% of the patients with “renal tumors combined with renal cysts” (P < 0.001); MCRNLMP accounted for 22.37% and 0.66% of patients with cysts’ growth rate ≥ 2.0 cm/year and < 2.0 cm/year, repectively. Of 76 MCRNLMP cases, after renal cyst de-topping decompression, no recurrence or metastasis was found in 9 patients who underwent nephron-sparing surgery or radical nephrectomy again, while only 1 suspicious recurrence was found by CT of 67 patients underwent actively monitored in postoperative 3-year follow-up.Conclusions MCRNLMP and renal cysts can be slightly identified through the potential predictors of Computed tomography (CT) scanning and growth rate. For MCRNLMP, partial nephrectomy is the first choice and radical nephrectomy should be avoided as much as possible, in addition, active monitoring can also be adopted after surgery to avoid unnecessary nephrectomy.
Background: Messenger ribonucleic acid (mRNA) vaccine has been considered as a potential therapeutic strategy and the next research hotspot, but their efficacy against prostate adenocarcinoma (PRAD) remains undefined. This study aimed to find potential antigens of PRAD for mRNA vaccine development and identify suitable patients for vaccination through immunophenotyping.Methods: Gene expression profiles and clinical information were obtained from TCGA and ICGC. GEPIA2 was used to calculate the prognostic index of the selected antigens. The genetic alterations were compared on cBioPortal and the correlation between potential antigen and immune infiltrating cells was explored by TIMER. ConsensusClusterPlus was used to construct a consistency matrix, and identify the immune subtypes. Graph learning-based dimensional reduction was performed to depict immune landscape. Boruta algorithm and LASSO logistic analysis were used to screen PRAD patients who may benefit from mRNA vaccine.Results: Seven potential tumor antigens selected were significantly positively associated with poor prognosis and the antigen-presenting immune cells (APCs) in PRAD, including ADA, FYN, HDC, NFKBIZ, RASSF4, SLC6A3, and UPP1. Five immune subtypes of PRAD were identified by differential molecular, cellular, and clinical characteristics in both cohorts. C3 and C5 had immune “hot” and immunosuppressive phenotype, On the contrary, C1&C2 had immune “cold” phenotype. Finally, the immune landscape characterization showed the immune heterogeneity among patients with PRAD.Conclusions: ADA, FYN, HDC, NFKBIZ, RASSF4, SLC6A3, and UPP1 are potential antigens for mRNA vaccine development against PRAD, and patients in type C1 and C2 are suitable for vaccination.
Background The association between computed tomography (CT) imaging characteristics and clinical growth rate of multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) have not been reported. Our study focused on the correlation of CT imaging and growth rate to investigate the distinguished characteristics in MCRNLMP versus renal cysts, and explore the optimized management.Methods Data regarding 1520 patients including 1,444 patients with renal cysts and 76 patients with MCRNLMP who underwent renal cyst decompression, radical nephrectomy, or nephron sparing surgery due to renal cystic disease between Jan 2013 and Dec 2021 in our institution were retrospectively collected and analyzed. Bosniak classification for imaging modality and the 2016 WHO criteria for clinic pathology were used for detection of MCRNLMP.Results In our study, MCRNLMP accounted for 1.48% of patients with “simple renal cysts”, 5.26% of the patients with “complex renal cysts”, and 12.11% of the patients with “renal tumors combined with renal cysts” (P < 0.001); MCRNLMP accounted for 22.37% and 0.66% of patients with cysts’ growth rate ≥ 2.0 cm/year and < 2.0 cm/year, repectively. Of 76 MCRNLMP cases, after renal cyst de-topping decompression, no recurrence or metastasis was found in 9 patients who underwent nephron-sparing surgery or radical nephrectomy again, while only 1 suspicious recurrence was found by CT of 67 patients underwent actively monitored in postoperative 3-year follow-up.Conclusions MCRNLMP can be slightly identified and divided into three types through the potential predictors of Computed tomography (CT) scanning and growth rate. For MCRNLMP, partial nephrectomy is the first choice and radical nephrectomy should be avoided as much as possible, in addition, active monitoring can also be adopted after surgery to avoid unnecessary nephrectomy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.